Angelika Borkowetz1,2,3, Andreas Blana1,2,4, Dirk Böhmer5,6, Hannes Cash2,7,8, Udo Ehrmann9, Tobias Franiel2,10,11, Thomas-Oliver Henkel1,2,12, Stefan Höcht5,13, Glen Kristiansen14,15,16, Stefan Machtens1,2,17, Peter Niehoff18,19, Tobias Penzkofer2,20, Michael Pinkawa18,21, Jan Philipp Radtke2,22, Wilfried Roth14,15,23, Ullrich Witzsch2,24, Roman Ganzer1,25, Heinz Peter Schlemmer10,26, Marc-Oliver Grimm1,27, Oliver W Hakenberg1,28, Martin Schostak1,2,8. 1. German Society of Urology (DGU), Berlin, Germany. 2. Working Group of Focal and Microtherapy of the German Society of Urology (DGU), Berlin, Germany. 3. Department of Urology, University Hospital, Technische Universität Dresden, Dresden, Germany. 4. Department of Urology, Fuerth Hospital, Fuerth, Germany. 5. Working Group Radiooncology German Cancer Society (ARO), Berlin, Germany. 6. Department of Radiooncology, University Hospital, Charite Berlin, Berlin, Germany. 7. ProUro, Berlin, Germany. 8. Department of Urology, University Hospital Magdeburg, Magdeburg, Germany. 9. Bundesverband Prostatakrebshilfe (BPS), Würzburg, Germany. 10. German Röntgen Society, Berlin, Germany. 11. Department of Diagnostic and Interventional Radiology, University Hospital Jena, Jena, Germany. 12. Urologie Praxis, Berlin, Germany. 13. Xcare Praxis für Strahlentherapie, Saarlouis, Germany. 14. German Society of Pathology, Berlin, Germany. 15. Bundesverband Deutscher Urologen, Berlin, Germany. 16. Department of Pathology, Universitätsklinikum Bonn, Bonn, Germany. 17. Department of Urology, GFO Hospitals Rhein-Berg, Marien-Hospital, Bergisch-Gladbach, Germany. 18. Berufsverband Deutscher Strahlentherapeuten, Berlin, Germany. 19. Department of Radiooncology, Sana Hospital Offenbach, Offenbach, Germany. 20. Department of Radiology, University Hospital Charite Berlin, Berlin, Germany. 21. Department of Radiooncology, MediClin Robert Janker Hospital, Bonn, Germany. 22. Department of Urology, University Hospital Essen, Essen, Germany. 23. Department of Pathology, University Hospital Mainz, Mainz, Germany. 24. Department of Urology, Krankenhaus Nordwest, Frankfurt, Germany. 25. Department of Urology, Asklepios Hospital Bad Tölz, Bad Tölz, Germany. 26. Department of Radiology, German Cancer Research Center (DKFZ), Heidelberg, Germany. 27. Department of Urology, University Hospital Jena, Jena, Germany. 28. Department of Urology, University Hospital Rostock, Rostock, Germany.
Abstract
BACKGROUND: Focal therapy (FT) is an option to treat localized prostate cancer (PCa) and preserve healthy prostate tissue in order to reduce known side effects from primary whole-gland treatment. The available FT modalities are manifold. Until now, national and international PCa guidelines have been cautious to propose recommendations regarding FT treatment since data from prospective controlled trials are lacking for most FT modalities. Moreover, none of the international guidelines provides a separate section on FT. In this purpose, we provide a synopsis of the consensus-based German S3 guidelines for a possible international use. SUMMARY: The recently published update of the German S3 guidelines, an evidence- and consensus-based guideline, provides a section on FT with recommendations for diagnostic work-up, indications, modalities, and follow-up. This section consists of 12 statements and recommendations for FT in the treatment of localized PCa. KEY MESSAGE: The German S3 guidelines on PCa are the first to incorporate recommendations for FT based on evidence and expert consensus including indication criteria for FT, pretreatment, and follow-up diagnostic pathways as well as an extended overview of FT techniques and the current supportive evidence.
BACKGROUND: Focal therapy (FT) is an option to treat localized prostate cancer (PCa) and preserve healthy prostate tissue in order to reduce known side effects from primary whole-gland treatment. The available FT modalities are manifold. Until now, national and international PCa guidelines have been cautious to propose recommendations regarding FT treatment since data from prospective controlled trials are lacking for most FT modalities. Moreover, none of the international guidelines provides a separate section on FT. In this purpose, we provide a synopsis of the consensus-based German S3 guidelines for a possible international use. SUMMARY: The recently published update of the German S3 guidelines, an evidence- and consensus-based guideline, provides a section on FT with recommendations for diagnostic work-up, indications, modalities, and follow-up. This section consists of 12 statements and recommendations for FT in the treatment of localized PCa. KEY MESSAGE: The German S3 guidelines on PCa are the first to incorporate recommendations for FT based on evidence and expert consensus including indication criteria for FT, pretreatment, and follow-up diagnostic pathways as well as an extended overview of FT techniques and the current supportive evidence.
Authors: Ron Golan; Adrien N Bernstein; Timothy D McClure; Art Sedrakyan; Neal A Patel; Dipen J Parekh; Leonard S Marks; Jim C Hu Journal: J Urol Date: 2017-04-19 Impact factor: 7.450
Authors: Nicolas Mottet; Roderick C N van den Bergh; Erik Briers; Thomas Van den Broeck; Marcus G Cumberbatch; Maria De Santis; Stefano Fanti; Nicola Fossati; Giorgio Gandaglia; Silke Gillessen; Nikos Grivas; Jeremy Grummet; Ann M Henry; Theodorus H van der Kwast; Thomas B Lam; Michael Lardas; Matthew Liew; Malcolm D Mason; Lisa Moris; Daniela E Oprea-Lager; Henk G van der Poel; Olivier Rouvière; Ivo G Schoots; Derya Tilki; Thomas Wiegel; Peter-Paul M Willemse; Philip Cornford Journal: Eur Urol Date: 2020-11-07 Impact factor: 20.096
Authors: Francesco Ziglioli; Marco Baciarello; Giada Maspero; Valentina Bellini; Tommaso Bocchialini; Domenico Cavalieri; Elena Giovanna Bignami; Umberto Maestroni Journal: Ann Med Surg (Lond) Date: 2020-05-30